FINWIRES · TerminalLIVE
FINWIRES

Mabwell (Shanghai) Bioscience Nets HK$1.2 Billion From Hong Kong IPO Ahead of Debut

By

Mabwell (Shanghai) Bioscience (HKG:2493, SHA:688062) raised HK$1.19 billion in net proceeds from its initial public offering in Hong Kong.

The final offer price was set at HK$27.64 per H-share, according to a Monday after-market filing with the Hong Kong Stock Exchange.

The China-based pharmaceutical firm offered 47.1 million H-shares in the global offering.

The Hong Kong public offer was 481.71 times subscribed, with a final allocation of 4.7 million shares, representing 10% of the total offering.

The international offering was 3.46 times subscribed, with a final allocation of 42.4 million shares, or 90% of the total offering.

Cornerstone investors, including Junshi Hong Kong, Sanjin International, Guohui (HK) Holdings, WuXi Biologics HealthCare Venture, and Splendid Zhonghe, were allotted a combined 15 million shares, according to the filing.

Mabwell is scheduled to debut on the Hong Kong bourse on Tuesday, April 28.

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

ASX 200ASX:COHASX:EVTASX:NXGASX:ORGASX:PDNASX:RHCASX:SX2ASX:TLXASX:TUAASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

BOM:524715NSE:SUNPHARMA